Literature DB >> 27919707

Autoimmune Cardiotoxicity of Cancer Immunotherapy.

Feixiong Cheng1, Joseph Loscalzo2.   

Abstract

Contemporary immunotherapies (e.g., immune checkpoint inhibitors), which enhance the immune response to cancer cells, improve clinical outcomes in several malignancies. A recent study reported the cases of two patients with metastatic melanoma who developed fatal myocarditis during ipilimumab and nivolumab combination immunotherapy; these examples highlight the risk of unbridled activation of the immune system.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cardio-oncology; immune checkpoint; immunotherapy.; ipilimumab; nivolumab

Mesh：

Substances：

Year:  2016        PMID： 27919707     DOI： 10.1016/j.it.2016.11.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  18 in total

1.  Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Authors:  Alexandre Reuben; Mariana Petaccia de Macedo; Jennifer McQuade; Aron Joon; Zhiyong Ren; Tiffany Calderone; Brandy Conner; Khalida Wani; Zachary A Cooper; Hussein Tawbi; Michael T Tetzlaff; Robert F Padera; Jean-Bernard Durand; Alexander J Lazar; Jennifer A Wargo; Michael A Davies
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

2.  Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.

Authors:  Matteo Sarocchi; Francesco Grossi; Eleonora Arboscello; Andrea Bellodi; Carlo Genova; Maria Giovanna Dal Bello; Erika Rijavec; Giulia Barletta; Giovanni Rossi; Federica Biello; Giorgio Ghigliotti; Marco Canepa; Michele Mussap; Claudio Brunelli; Paolo Spallarossa
Journal:  Oncologist       Date:  2018-03-22

Review 3.  Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.

Authors:  Feixiong Cheng; Han Liang; Atul J Butte; Charis Eng; Ruth Nussinov
Journal:  Pharmacol Rev       Date:  2018-12-13       Impact factor: 25.468

4.  In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.

Authors:  Chuipu Cai; Jiansong Fang; Pengfei Guo; Qi Wang; Huixiao Hong; Javid Moslehi; Feixiong Cheng
Journal:  J Chem Inf Model       Date:  2018-05-10       Impact factor: 4.956

Review 5.  T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

Authors:  Karin H Simons; Alwin de Jong; J Wouter Jukema; Margreet R de Vries; Ramon Arens; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

6.  Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.

Authors:  W Lu; F Cheng; W Yan; X Li; X Yao; W Song; M Liu; X Shen; H Jiang; J Chen; J Li; J Huang
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

Review 7.  Cardio-Oncology: mechanisms of cardiovascular toxicity.

Authors:  Timothy M Markman; Maurie Markman
Journal:  F1000Res       Date:  2018-01-25

Review 8.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

Review 9.  Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.

Authors:  Jennifer M Yoest
Journal:  Immunotargets Ther       Date:  2017-10-10

Review 10.  Cardiotoxicity of Anticancer Therapeutics.

Authors:  Jerry Dong; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2018-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.